Journal
CELL METABOLISM
Volume 34, Issue 11, Pages 1732-+Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2022.10.007
Keywords
-
Categories
Ask authors/readers for more resources
The MGAT2 inhibitor BMS-963272 shows promise as a potential treatment for NASH. It decreases inflammation and fibrosis, improves blood biomarkers, increases gut hormone levels, and reduces body weight, as demonstrated in rodent and primate models as well as in obese human subjects.
Monoacylglycerol acyltransferase 2 (MGAT2) is an important enzyme highly expressed in the human small intestine and liver for the regulation of triglyceride absorption and homeostasis. We report that treatment with BMS-963272, a potent and selective MGAT2 inhibitor, decreased inflammation and fibrosis in CDAHFD and STAM, two murine nonalcoholic steatohepatitis (NASH) models. In high-fat-diet-treated cyno-molgus monkeys, in contrast to a selective diacylglycerol acyltransferase 1 (DGAT1) inhibitor, BMS-963272 did not cause diarrhea. In a Phase 1 multiple-dose trial of healthy human adults with obesity (NCT04116632), BMS-963272 was safe and well tolerated with no treatment discontinuations due to adverse events. Consis-tent with the findings in rodent models, BMS-963272 elevated plasma long-chain dicarboxylic acid, indi-cating robust pharmacodynamic biomarker modulation; increased gut hormones GLP-1 and PYY; and decreased body weight in human subjects. These data suggest MGAT2 inhibition is a promising therapeutic opportunity for NASH, a disease with high unmet medical needs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available